Beverly JCG   

Beverly : The Medical Beauty Star

Sleeping dragon...waiting for it to roar.

 

Accumulating.

 

Accumulating. Turn profit company.
Should start to rise next week.

SmallSmall      ( Date: 13-Aug-2025 10:51) Posted: Day high @ $0.013....Can go higher?

 

Day high @ $0.013....Can go higher?

 

Market reacted positively to the Beverly announcement which is in line with my write up. 👍  

sklong138      ( Date: 13-Aug-2025 04:21) Posted: Here' s a concise comparison of Beverly JCG Ltd.' s financial performance for Q2 2025 (ended 30 June 2025) versus Q2 2024:   ### **Revenue & Profitability** - **Revenue**:      - **Q2 2025**: S$2.32 million (**+57% YoY**)      - *Driven by growth in aesthetic medical services (Malaysia)*.    - **Gross Profit**:      - **Q2 2025**: S$1.26 million (**+56% YoY**), margin at **54%** (vs. 55% in Q2 2024).    - **Net Profit**:      - **Q2 2025**: **Profit of S$38k** (vs. **Loss of S$661k** in Q2 2024).      - *H1 2025: Profit of S$55k (vs. Loss of S$1.32m in H1 2024)*.      ### **Key Changes in Expenses** - **Administrative Expenses**:      - **&darr 25% YoY** (S$1.08m vs. S$1.44m) due to cost-cutting.    - **Distribution Expenses**:      - **&uarr > 100% YoY** (S$0.25m vs. S$0.05m) from higher marketing costs.    - **Finance Costs**:      - **&darr 14% YoY** (S$0.03m vs. S$0.04m).      ### **Balance Sheet Highlights** - **Liquidity**:      - Cash: **S$544k** (vs. S$858k at end-2024).    - **Liabilities**:      - Current liabilities **&darr 37%** to S$4.82m (driven by lower payables).    - **Net Position**:      - Group net liabilities **improved** to S$2.78m (vs. S$5.34m at end-2024).      ### **Operational & Strategic Notes** - **Segment Performance**:      - Aesthetic medical (Malaysia) drove **all revenue** trading segment inactive.    - **Going Concern**:      - Despite profitability, negative working capital (S$3.1m deficit) and reliance on shareholder funding (S$1.6m raised via shares in 2025) remain risks.    - **Outlook**:      - Focus on monetizing excess capacity and cost efficiency in Asia' s growing aesthetic market (CAGR 13.6%).      ### **Summary**    Beverly JCG turned profitable in Q2 2025 on strong revenue growth and cost control. However, financial fragility persists, requiring ongoing capital support and operational discipline to sustain recovery.

 

Here' s a concise comparison of Beverly JCG Ltd.' s financial performance for Q2 2025 (ended 30 June 2025) versus Q2 2024:

 

the bulk buy up at 1.0c, mostly after 4pm buyin. Someone sold 4m+ at 1.2c , could be just buy back 1.0c in open market topocket the difference.

 

This penny stock looks interesting @ this level $0.01
Can run like CapAllianz?

 

Really nobody want type of share ? No volume leh...

ysh2006      ( Date: 21-Feb-2024 05:28) Posted: Only 2.4% people buy the right issue shares.....nobody want leh ?

 

Only 2.4% people buy the right issue shares.....nobody want leh ?

 

No logic to buy the right issue more expensive than mother shares 😕

SmallSmall      ( Date: 07-Feb-2024 14:44) Posted: Buyers building up... Right issue price $0.035. Now $0.025

 

Buyers building up... Right issue price $0.035. Now $0.025

 

https://links.sgx.com/1.0.0/corporate-announcements/7GS54QR4HVJMXTSW/f161f08061dafded1e965e9ddc6dd1c215d8be3653a49150bdc2c43312f1cb91 Don't you find it funny that the company has to post it minutes of the last EGM after so long? Existing shareholders are angry and company just ask the small shareholders to suck thumb. DYDD folks. Tsunami coming

 

Beverly JCG is just one of the many companies listed on SGX that will hurt retail investors in Singapore. It can be seen in their sudden changes in their corporate actions timeline for Share Consolidation ex date and credit date. They have not announced their rights date. It's all very sus to me. This company have issued too many shares from their past actions which will just erode away the old shareholders. They are looking for new ones take over.

 

This kind of consolidation price can lose half easily. Better to short

 

Thank thought of buying some to trade

darkhorse88      ( Date: 08-Jan-2024 12:21) Posted: Consolidating to sell down before right issues. Don't get trap.

 

Consolidating to sell down before right issues. Don't get trap.

 

Share Consolidation 50 to 1.
Sgx announcement

 

Beverly JCG, a reputable brand in Malaysia with multi award-winning integrated beauty and wellness medical centres, has announced its 3Q FY2023 results on 10 Nov 2023.
https://www.smallcapasia.com/this-aesthetics-healthcare-stock-is-unlocking-growth-through-strategic-acquisitions7-key-things-you-need-to-know-about-niks-professionals-ipo-another-medical-provider-to-join-the-defensive-healthcare/

 

The company is going to call for EGM soon and minority shareholders have no say in this share diluting exercise which is extremely painful. SGX Catalist Index is the worse in the world and SGX do not care at all. The forum and partners should continue to flag out such companies to the public.